The Ministry of Health has finally published yesterday's update: EBOLA DRC - Evolution of the response to the Ebola outbreak in the provinces of North Kivu and Ituri on Wednesday, June 19, 2019. Excerpt from the Google translation:
EVOLUTION OF THE EBOLA EPIDEMIC IN THE PROVINCES OF NORTH KIVU AND ITURI
Wednesday, June 19, 2019
The epidemiological situation of the Ebola Virus Disease dated June 18, 2019:
• Since the beginning of the epidemic, the cumulative number of cases is 2,190, 2,096 confirmed and 94 probable. In total, there were 1,470 deaths (1,376 confirmed and 94 probable) and 604 people healed.
• 325 suspected cases under investigation;
• 9 new confirmed cases, including 3 in Beni, 3 in Mabalako, 2 in Mandima and 1 in Musienene;
º 11 new confirmed case deaths:
º 4 community deaths, 2 in Mabalako, 1 in Mandima and 1 in Beni;
º 7 deaths at CTE, including 4 in Beni, 2 in Mabalako and 1 in Katwa;
• 2 new healed from the CTE of Mabalako.
/! \ The data presented in this table are subject to change later, after extensive investigations and after redistribution of cases and deaths in their health areas.
FIGURES OF THE RESPONSE
137,316 people vaccinated
• In-depth review of the vaccination database.
• Persons vaccinated by health zone: 34,226 in Katwa, 26,574 in Beni, 18,563 in Butembo, 12,441 in Mabalako, 6,587 in Mandima, 4,896 in Kalunguta, 3,398 in Goma, 3,248 in Komanda, 3,089 in Musienene, 2,569 in Oicha, 2,461 in Masereka , 2,137 to Lubero, 2,045 to Vuhovi, 1,980 to Kayna, 1,918 to Kyondo, 1,506 to Bunia, 1,411 to Mutwanga, 1,116 to Rwampara, 1,040 to Biena, 724 to Mangurujipa, 690 to Rutshuru, 597 to Alimbongo, 527 to Nyankunde, 420 in Mambasa, 355 in Tchomia, 342 in Kirotshe, 333 in Lolwa, 250 in Mweso, 245 in Kibirizi, 161 in Nyiragongo, 97 in Watsa (Haut-Uélé) and 13 in Kisangani.
• Among the vaccinated persons, 37,942 are high-risk contacts (CHR), 69,008 are contacts of contacts (CC), and 30,366 are first-line providers (PPL).
• The only vaccine to be used in this outbreak is the rVSV-ZEBOV vaccine, manufactured by the pharmaceutical group Merck, following approval by the Ethics Committee in its decision of 19 May 2018.
